Brown Capital Management LLC Has $17.36 Million Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Brown Capital Management LLC trimmed its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 13.2% during the third quarter, HoldingsChannel reports. The fund owned 420,879 shares of the company’s stock after selling 64,035 shares during the quarter. Brown Capital Management LLC’s holdings in Inari Medical were worth $17,357,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NARI. GAMMA Investing LLC raised its position in Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares during the last quarter. Covestor Ltd increased its position in shares of Inari Medical by 30.2% during the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares during the period. KBC Group NV raised its position in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $49.00 on Thursday. The stock has a fifty day simple moving average of $45.52 and a two-hundred day simple moving average of $47.19. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13.

Insider Transactions at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares in the company, valued at $25,643,080.28. The trade was a 10.69 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NARI. Robert W. Baird raised their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 29th. Truist Financial lifted their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price target on the stock. Stifel Nicolaus started coverage on Inari Medical in a report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective for the company. Finally, Piper Sandler raised their target price on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Inari Medical presently has a consensus rating of “Hold” and an average target price of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.